These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31338095)

  • 21. Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.
    Diomede L; Nyoka S; Pastori C; Scotti L; Zambon A; Sherman G; Gray CM; Sarzotti-Kelsoe M; Lopalco L
    J Virol; 2012 Apr; 86(8):4129-38. PubMed ID: 22301151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail.
    Durham ND; Yewdall AW; Chen P; Lee R; Zony C; Robinson JE; Chen BK
    J Virol; 2012 Jul; 86(14):7484-95. PubMed ID: 22553332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maturation-induced cloaking of neutralization epitopes on HIV-1 particles.
    Joyner AS; Willis JR; Crowe JE; Aiken C
    PLoS Pathog; 2011 Sep; 7(9):e1002234. PubMed ID: 21931551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
    Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
    PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions.
    Carravilla P; Chojnacki J; Rujas E; Insausti S; Largo E; Waithe D; Apellaniz B; Sicard T; Julien JP; Eggeling C; Nieva JL
    Nat Commun; 2019 Jan; 10(1):78. PubMed ID: 30622256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif.
    Smith SA; Derdeyn CA
    J Virol; 2017 May; 91(9):. PubMed ID: 28250119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity.
    Sojar H; Baron S; Sullivan JT; Garrett M; van Haaren MM; Hoffman J; Overbaugh J; Doranz BJ; Hicar MD
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31217246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.
    Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M
    J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions.
    Cavacini LA; Duval M; Robinson J; Posner MR
    AIDS; 2002 Dec; 16(18):2409-17. PubMed ID: 12461414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DEER Spectroscopy Measurements Reveal Multiple Conformations of HIV-1 SOSIP Envelopes that Show Similarities with Envelopes on Native Virions.
    Stadtmueller BM; Bridges MD; Dam KM; Lerch MT; Huey-Tubman KE; Hubbell WL; Bjorkman PJ
    Immunity; 2018 Aug; 49(2):235-246.e4. PubMed ID: 30076100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.
    Yasmeen A; Ringe R; Derking R; Cupo A; Julien JP; Burton DR; Ward AB; Wilson IA; Sanders RW; Moore JP; Klasse PJ
    Retrovirology; 2014 May; 11():41. PubMed ID: 24884783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.
    Liu P; Overman RG; Yates NL; Alam SM; Vandergrift N; Chen Y; Graw F; Freel SA; Kappes JC; Ochsenbauer C; Montefiori DC; Gao F; Perelson AS; Cohen MS; Haynes BF; Tomaras GD
    J Virol; 2011 Nov; 85(21):11196-207. PubMed ID: 21865397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.
    Pritchard LK; Harvey DJ; Bonomelli C; Crispin M; Doores KJ
    J Virol; 2015 Sep; 89(17):8932-44. PubMed ID: 26085151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.
    Bouvin-Pley M; Morgand M; Meyer L; Goujard C; Moreau A; Mouquet H; Nussenzweig M; Pace C; Ho D; Bjorkman PJ; Baty D; Chames P; Pancera M; Kwong PD; Poignard P; Barin F; Braibant M
    J Virol; 2014 Dec; 88(23):13910-7. PubMed ID: 25231299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
    Huang J; Kang BH; Pancera M; Lee JH; Tong T; Feng Y; Imamichi H; Georgiev IS; Chuang GY; Druz A; Doria-Rose NA; Laub L; Sliepen K; van Gils MJ; de la Peña AT; Derking R; Klasse PJ; Migueles SA; Bailer RT; Alam M; Pugach P; Haynes BF; Wyatt RT; Sanders RW; Binley JM; Ward AB; Mascola JR; Kwong PD; Connors M
    Nature; 2014 Nov; 515(7525):138-42. PubMed ID: 25186731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1.
    Nyambi PN; Burda S; Bastiani L; Williams C
    J Immunol Methods; 2001 Jul; 253(1-2):253-62. PubMed ID: 11384686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.